{"id":2832,"date":"2025-02-06T14:22:23","date_gmt":"2025-02-06T11:22:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2832"},"modified":"2025-11-03T20:24:39","modified_gmt":"2025-11-03T17:24:39","slug":"percheron-therapeutics-announces-terminated-of-atl1102-study-for-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/hi\/percheron-therapeutics-announces-terminated-of-atl1102-study-for-dmd\/","title":{"rendered":"\u092a\u0947\u0930\u091a\u0947\u0930\u0949\u0928 \u0925\u0947\u0930\u0947\u092a\u094d\u092f\u0942\u091f\u093f\u0915\u094d\u0938 \u0928\u0947 \u0921\u0940\u090f\u092e\u0921\u0940 \u0915\u0947 \u0932\u093f\u090f \u090f\u091f\u0940\u090f\u09321102 \u0905\u0927\u094d\u092f\u092f\u0928 \u0915\u094b \u0938\u092e\u093e\u092a\u094d\u0924 \u0915\u0930\u0928\u0947 \u0915\u0940 \u0918\u094b\u0937\u0923\u093e \u0915\u0940"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">\u201cOne way or other, we don\u2019t think ATL-1102 can remain the centerpiece of the story put forward to investors,\u201d Garner told investors in a webinar this morning.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In summary, the trial failed to detect any meaningful difference between the boys actively treated with ATL-1102, compared with the placebo cohort. [Read More: <a href=\"https:\/\/dmdwarrior.com\/percheron-disappointed-in-avicursen-atl1102-study-for-duchenne-dmd\/\">Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)<\/a>]<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"youtube-embed\" data-video_id=\"mSEmhOawVlc\"><iframe title=\"Webinar Recording \u2013 Phase IIb results discussion.\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/mSEmhOawVlc?feature=oembed&#038;enablejsapi=1\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Read More<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Clinical Trials for Duchenne (List of All Researches)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cOne way or other, we don\u2019t think ATL-1102 can remain the centerpiece of the story put forward to investors,\u201d Garner told investors in a webinar this morning. In summary, the trial failed to detect any meaningful difference between the boys actively treated with ATL-1102, compared with the placebo cohort. [Read More: Percheron Disappointed in Avicursen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2835,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[114,113,112,115],"class_list":["post-2832","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-atl1102","tag-avicursen","tag-percheron","tag-percheron-therapeutics"],"subtitle":"\u092a\u0947\u0930\u091a\u0947\u0930\u0949\u0928 \u0925\u0947\u0930\u0947\u092a\u094d\u092f\u0942\u091f\u093f\u0915\u094d\u0938 \u0928\u0947 \u0915\u0939\u093e \u0915\u093f \u0935\u0939 \u0926\u093f\u0938\u0902\u092c\u0930 \u092e\u0947\u0902 \u0921\u094d\u092f\u0942\u0936\u0947\u0928 \u092e\u0938\u094d\u0915\u0941\u0932\u0930 \u0921\u093f\u0938\u094d\u091f\u094d\u0930\u0949\u092b\u0940 \u092a\u0930\u0940\u0915\u094d\u0937\u0923 \u0915\u0947 \u0905\u0938\u092b\u0932 \u0939\u094b\u0928\u0947 \u0915\u0947 \u092c\u093e\u0926 \u0905\u092a\u0928\u0940 \u092a\u094d\u0930\u092e\u0941\u0916 \u0926\u0935\u093e \u0909\u092e\u094d\u092e\u0940\u0926\u0935\u093e\u0930 \u0915\u094b \u092a\u0942\u0930\u0940 \u0924\u0930\u0939 \u0938\u0947 \u0924\u094d\u092f\u093e\u0917 \u0926\u0947\u0917\u093e\u0964 \u092a\u0947\u0930\u091a\u0947\u0930\u0949\u0928 \u0925\u0947\u0930\u0947\u092a\u094d\u092f\u0942\u091f\u093f\u0915\u094d\u0938 \u0928\u0947 \u0921\u0940\u090f\u092e\u0921\u0940 \u0915\u0947 \u0932\u093f\u090f \u090f\u091f\u0940\u090f\u09321102 \u0905\u0927\u094d\u092f\u092f\u0928 \u0915\u094b \u0938\u092e\u093e\u092a\u094d\u0924 \u0915\u0930\u0928\u0947 \u0915\u0940 \u0918\u094b\u0937\u0923\u093e \u0915\u0940\u0964","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/posts\/2832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/comments?post=2832"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/posts\/2832\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/media\/2835"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/media?parent=2832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/categories?post=2832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/tags?post=2832"}],"curies":[{"name":"\u0921\u092c\u094d\u0932\u094d\u092f\u0942\u092a\u0940","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}